NCT02791087

Brief Summary

CFD simulations in this study provide detailed hemodynamics information, which cannot be obtained from cardiac images alone. The investigators hypothesize that our proposed simulations will provide strong correlation between hemodynamic parameters, such as WSSG and SPA, and clinically identified graft stenosis. These correlations will allow the investigators to identify the future patients at high risk of graft stenosis and lead to future researches on optimizing and refining surgical plans, such as finding optimal proximal and distal anastomoses locations, optimal graft length and diameter, which could lead to improved longevity of the graft. Once CFD coupled shape optimizer is validated, it could be part of the surgical simulator to help in training the next generation physicians. It could provide new viewpoints for assessing whether some modified surgical techniques are better or not. It could also aid in designing and evaluating the vascular medical devices, including stent, artificial graft, and etc., which would lead to better surgical outcome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2013

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

May 31, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 6, 2016

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2018

Completed
Last Updated

June 7, 2019

Status Verified

September 1, 2017

Enrollment Period

5.3 years

First QC Date

May 31, 2016

Last Update Submit

June 6, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evidence of allergic reaction due to CTA scan contrast

    Within first day after scan

Study Arms (2)

Coronary Artery Disease for CABG

Patients undergoing or underwent Coronary Bypass Surgery with at least one saphenous vein graft. Intra-operative graft flow rate measurement will be done during CABG surgery.

Other: Computed Tomography AngiographyOther: Intra-operative graft flow rate measurement

Stable/Unstable Angina

Patients with no known history of coronary artery disease undergoing Computed Tomography Angiography scan due to stable/Unstable Angina.

Other: Computed Tomography Angiography

Interventions

The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.

Coronary Artery Disease for CABGStable/Unstable Angina

This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.

Coronary Artery Disease for CABG

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Potential patients scheduled for Coronary Bypass Surgery identified at NHCS cardiology inpatient and patients with stable/unstable angina from cardiology inpatient and outpatient clinic.

You may qualify if:

  • Aged 21-80.
  • Undergoing or underwent CABG with at least one saphenous vein graft. (Only for recruitment of CABG patients)
  • No known history of coronary artery disease (only for recruitment of volunteers with Stable/unstable angina).

You may not qualify if:

  • Individuals unable to provide informed consent.
  • Non-cardiac illness with life expectancy \<2 years.
  • Pregnant state.
  • Allergy to iodinated contrast.
  • Significant arrhythmia; heart rate ≥ 100 beats/min; systolic blood pressure ≤90 mmHg.
  • Renal dysfunction(Glomerular filtration rate (GFR) \<30 mL/min/1.73m2).
  • Contraindication to beta blockers or nitroglycerin.
  • Canadian Cardiovascular Society class IV angina.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Heart Centre Singapore

Singapore, 169609, Singapore

Location

MeSH Terms

Conditions

Coronary Artery DiseaseAngina, StableAngina, Unstable

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesAngina PectorisChest PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Junmei Zhang

    National Heart Centre Singapore

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2016

First Posted

June 6, 2016

Study Start

June 1, 2013

Primary Completion

October 1, 2018

Study Completion

October 1, 2018

Last Updated

June 7, 2019

Record last verified: 2017-09

Data Sharing

IPD Sharing
Will not share

Locations